Ligand-binding assay (LBA) is a method used to quantify how well a substance binds to a specific target, especially in the evaluation of antibodies. It provides essential evidence on whether an antibody candidate can effectively bind to its intended target. This is particularly crucial for therapeutic antibodies, as their ability to bind to specific targets influences their clinical effectiveness and safety. Consequently, regulatory bodies agencies such as the FDA and EMA commonly require comprehensive LBA profiles as part of the investigational new drug (IND) submission package.
Fig.1 Key challenges for LBAs in the development phases of a biologic drug from discovery to regulatory approval and beyond.1, 3
With our extensive experience and expertise in therapeutic antibody discovery and development, Creative Biolabs provides exceptional LBA services to assist customers in evaluating and confirming the binding properties of your antibodies.
At Creative Biolabs, we specialize in offering cutting-edge LBA services that cater to various therapeutic molecules including peptides, recombinant proteins, monoclonal antibodies, and oligonucleotides. Our assays are not limited to biotherapeutics but also cover anti-drug antibodies, cell therapies, and gene therapies. What sets us apart is our commitment to conducting all assays in GLP-compliant laboratories, ensuring adherence to regulatory guidelines for robust and reproducible results. Our team of experienced professionals will guide you in selecting the most suitable assay reagents and formats, customizing experiment protocols, and delivering comprehensive and reliable outcomes.
Furthermore, we extend our expertise to immunogenicity testing and Fc binding profiling using our state-of-the-art LBA platform. Trust Creative Biolabs for your binding characterization demands and advance your research with assurance.
Fig.2 Highlights of our LBA services.
Creative Biolabs offers a wide range of LBA methods, which include:
|
Enzyme-linked immunosorbent assay (ELISA), automated ELISA systems, radioimmunoassay (RIA), enzyme immunoassay (EIA), fluorescence immunoassay (FIA), immunoradiometric assay (IRMA) |
|
Surface plasmon resonance (SPR) assay, bio-layer interferometry (BLI) assay, scintillation proximity assay (SPA), LC-MS detection |
|
Oligonucleotide hybridization assays, branched chain DNA Assay (bDNA) |
Method: Radioimmunoassay (RIA)
Summary: Evaluating drug-target binding kinetics is crucial for determining drug efficacy in vivo. In this study, association binding experiments are conducted to assess the binding kinetics of histamine H1 receptor (H1R) antagonists. The experiments involve competing with radiolabelled probes, providing valuable insights into the binding dynamics of these compounds.
Fig.3 H1R binds to [3H] an antihistamine small molecular agent, [3H] an H1-receptor antagonist, and [3H] a histamine H1 antagonist, respectively.2, 4
Fig.4 Radioligand binding assay comparing the binding of [3H] an antihistamine small molecular agent and [3H] a histamine H1 antagonist at the H1 receptor in the presence of unlabeled competitors at 25°C.2, 5
Q1: What are the requirements for ligand binding assay?
A1: Our LBA services need customers to provide basic information about your testing samples. Leveraging this information, our experts make the most appropriate experiment schemes for your project performance. If you have any specific requirements or questions, please feel free to reach out to our team for personalized assistance.
For more details about our ligand binding assay, please contact us immediately.
References
For Research Use Only.